{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:01:35Z","timestamp":1777888895034,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZB20230250"],"award-info":[{"award-number":["GZB20230250"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFD1700500"],"award-info":[{"award-number":["2023YFD1700500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22422702"],"award-info":[{"award-number":["22422702"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drudis.2026.104622","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:12:03Z","timestamp":1770624723000},"page":"104622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting farnesyltransferase for cancer therapy and beyond"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-605X","authenticated-orcid":false,"given":"Long-Can","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104622_b0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","article-title":"The metabolic landscape of RAS-driven cancers from biology to therapy","volume":"2","author":"Mukhopadhyay","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.drudis.2026.104622_b0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tcb.2022.09.002","article-title":"The role of RAS oncogenes in controlling epithelial mechanics","volume":"33","author":"Nyga","year":"2023","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.drudis.2026.104622_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104622_b0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-023-00993-3","article-title":"Mutant HRas signaling and rationale for use of farnesyltransferase inhibitors in head and neck squamous cell carcinoma","volume":"18","author":"Wang","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.drudis.2026.104622_b0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","article-title":"Classification of KRAS-activating mutations and the implications for therapeutic intervention","volume":"12","author":"Johnson","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104622_b0030","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1523\/JNEUROSCI.0610-22.2023","article-title":"Impaired autophagic-lysosomal fusion in Parkinson's patient midbrain neurons occurs through loss of ykt6 and is rescued by farnesyltransferase inhibition","volume":"43","author":"Pitcairn","year":"2023","journal-title":"J Neurosci"},{"key":"10.1016\/j.drudis.2026.104622_b0035","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/bloodadvances.2024012806","article-title":"Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed\/refractory peripheral T-cell lymphoma","volume":"8","author":"Witzig","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2026.104622_b0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tips.2024.12.008","article-title":"Protein prenylation in mechanotransduction: implications for disease and therapy","volume":"46","author":"Chen","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104622_b0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-025-02309-7","article-title":"Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics","volume":"24","author":"Xu","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104622_b0050","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1073\/pnas.93.9.4454","article-title":"Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells","volume":"93","author":"James","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104622_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113006","article-title":"Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway","volume":"211","author":"Korzeniecki","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104622_b0060","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1158\/0008-5472.CAN-06-0185","article-title":"HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53\/p21 pathway","volume":"66","author":"Wang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104622_b0065","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/1078-0432.CCR-03-0412","article-title":"Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors","volume":"10","author":"Khuri","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104622_b0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1021\/acs.jmedchem.3c01828","article-title":"Emerging drug targets for antimalarial drug discovery: validation and insights into molecular mechanisms of function","volume":"67","author":"Cheuka","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104622_b0075","doi-asserted-by":"crossref","first-page":"12948","DOI":"10.1073\/pnas.241407898","article-title":"The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics","volume":"98","author":"Long","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104622_b0080","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/acs.biochem.0c00081","article-title":"Protein farnesyltransferase catalyzes unanticipated farnesylation and geranylgeranylation of shortened target sequences","volume":"59","author":"Ashok","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104622_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/g3journal\/jkad094","article-title":"A comprehensive in vivo screen of yeast farnesyltransferase activity reveals broad reactivity across a majority of CXXX sequences","volume":"13","author":"Kim","year":"2023","journal-title":"G3 (Bethesda)"},{"key":"10.1016\/j.drudis.2026.104622_b0090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1039\/C2MD20299A","article-title":"Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections","volume":"4","author":"Ochocki","year":"2013","journal-title":"Medchemcomm"},{"key":"10.1016\/j.drudis.2026.104622_b0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104622_b0100","doi-asserted-by":"crossref","first-page":"D433","DOI":"10.1093\/nar\/gky1159","article-title":"15 years of PhosphoSitePlus(R): integrating post-translationally modified sites, disease variants and isoforms","volume":"47","author":"Hornbeck","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104622_b0105","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1210\/endo.141.4.7411","article-title":"Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia","volume":"141","author":"Draznin","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2026.104622_b0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.ijo.0802189","article-title":"Dominant negative alpha-subunit of farnesyl- and geranylgeranyl-transferase I inhibits insulin-induced differentiation of 3T3-L1 pre-adipocytes","volume":"27","author":"Solomon","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.drudis.2026.104622_b0115","doi-asserted-by":"crossref","first-page":"e4414","DOI":"10.1002\/pro.4414","article-title":"Mechanistic insight into impact of phosphorylation on the enzymatic steps of farnesyltransferase","volume":"31","author":"Pekel","year":"2022","journal-title":"Protein Sci"},{"key":"10.1016\/j.drudis.2026.104622_b0120","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/anie.200400618","article-title":"Recognition of proline-rich motifs by protein-protein-interaction domains","volume":"44","author":"Ball","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2026.104622_b0125","doi-asserted-by":"crossref","first-page":"15789","DOI":"10.1074\/jbc.M212525200","article-title":"Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation","volume":"278","author":"Jiang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104622_b0130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2015.10.148","article-title":"Mammalian farnesyltransferase \u03b1 subunit regulates vacuolar protein sorting-associated protein 4A (Vps4A) - dependent intracellular trafficking through recycling endosomes","volume":"468","author":"Kubala","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104622_b0135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12964-022-00929-w","article-title":"Impact of a conserved N-terminal proline-rich region of the alpha-subunit of CAAX-prenyltransferases on their enzyme properties","volume":"20","author":"Hagemann","year":"2022","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.drudis.2026.104622_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101451","article-title":"New indazole-indolizine-triazine hybrid molecules with farnesyltransferase inhibitory activity","volume":"7","author":"Ciurl\u0103-Lucescu","year":"2024","journal-title":"Results Chem"},{"key":"10.1016\/j.drudis.2026.104622_b0145","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.2174\/0115701808323543241018053705","article-title":"Exploring the antitumor potential of new indazole-indolizines designed by molecular hybridization","volume":"21","author":"Ciurla-Lucescu","year":"2024","journal-title":"Lett Drug Des Discovery"},{"key":"10.1016\/j.drudis.2026.104622_b0150","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41467-021-21066-x","article-title":"High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming","volume":"12","author":"Hu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104622_b0155","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","article-title":"Phenotypic drug discovery: recent successes, lessons learned and new directions","volume":"21","author":"Vincent","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104622_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2018.12.007","article-title":"Natural product derived privileged scaffolds in drug discovery","volume":"52","author":"Davison","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.drudis.2026.104622_b0165","article-title":"Green synthesis of a new series of pyroglutamides targeting human farnesyltransferase","volume":"30","author":"Dufr\u00e9noy","year":"2022","journal-title":"Sustainable Chem Pharm"},{"key":"10.1016\/j.drudis.2026.104622_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127149","article-title":"Ultrasounds-mediated 10-seconds synthesis of chalcones as potential farnesyltransferase inhibitors","volume":"30","author":"Homerin","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104622_b0175","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/ph16060888","article-title":"Phenothiazine- and carbazole-cyanochalcones as dual inhibitors of tubulin polymerization and human farnesyltransferase","volume":"16","author":"Zuba\u0219","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2026.104622_b0180","doi-asserted-by":"crossref","first-page":"423","DOI":"10.34172\/apb.2020.051","article-title":"Design, Synthesis and biological evaluation of novel piperazinone derivatives as cytotoxic agents","volume":"10","author":"Ghasemi","year":"2020","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.drudis.2026.104622_b0185","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200263","article-title":"Structure-activity relationship study to improve cytotoxicity and selectivity of lonafarnib against breast cancer cells","volume":"356","author":"Hongnak","year":"2023","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.drudis.2026.104622_b0190","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tips.2024.06.001","article-title":"Innovating cancer drug discovery with refined phenotypic screens","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104622_b0195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1021\/acsmedchemlett.0c00551","article-title":"Discovery of an anion-dependent farnesyltransferase inhibitor from a phenotypic screen","volume":"12","author":"Bukhtiyarova","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104622_b0200","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1021\/acsomega.9b02263","article-title":"Discovery of Lonafarnib-like compounds: pharmacophore modeling and molecular dynamics studies","volume":"5","author":"Rampogu","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104622_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130667","article-title":"Computational investigation of novel farnesyltransferase inhibitors using 3D-QSAR pharmacophore modeling, virtual screening, molecular docking and molecular dynamics simulation studies: a new insight into cancer treatment","volume":"1241","author":"Safavi","year":"2021","journal-title":"J Mol Struct"},{"key":"10.1016\/j.drudis.2026.104622_b0210","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/jccs.202100037","article-title":"Peptide scaffold-derived peptidomimetic farnesyltransferase inhibitors","volume":"68","author":"Yang","year":"2021","journal-title":"J Chin Chem Soc"},{"key":"10.1016\/j.drudis.2026.104622_b0215","doi-asserted-by":"crossref","first-page":"13753","DOI":"10.1021\/acs.jmedchem.2c00902","article-title":"Structure-guided discovery of potent antifungals that prevent ras signaling by inhibiting protein farnesyltransferase","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104622_b0220","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-18-3399","article-title":"Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors","volume":"25","author":"Kazi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104622_b0225","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/a-1422-1885","article-title":"vHTS and 3D-QSAR for the identification of novel phyto-inhibitors of farnesyltransferase: validation of ascorbic acid inhibition of farnesyltransferase in an animal model of breast cancer","volume":"71","author":"Samuel","year":"2021","journal-title":"Drug Res"},{"key":"10.1016\/j.drudis.2026.104622_b0230","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1038\/s41467-024-49360-4","article-title":"Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies","volume":"15","author":"Figarol","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104622_b0235","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104622_b0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-021-00149-4","article-title":"Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant\/BRAF V600E lung adenocarcinoma patient","volume":"5","author":"Ribeiro","year":"2021","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.drudis.2026.104622_b0245","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/14656566.2021.1873952","article-title":"Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"22","author":"Leenhardt","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.drudis.2026.104622_b0250","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-23-0282","article-title":"Tipifarnib potentiates the antitumor effects of PI3Kalpha inhibition in PIK3CA- and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity","volume":"83","author":"Smith","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104622_b0255","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-21-0142","article-title":"Concurrent inhibition of ERK and farnesyltransferase suppresses the growth of HRAS mutant head and neck squamous cell carcinoma","volume":"21","author":"Javaid","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2026.104622_b0260","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41388-024-03095-0","article-title":"Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors","volume":"43","author":"Nigam","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104622_b0265","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.760055","article-title":"Trametinib inhibits the growth and aerobic glycolysis of glioma cells by targeting the PKM2\/c-Myc axis","volume":"12","author":"Gao","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104622_b0270","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41416-024-02586-x","article-title":"Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors","volume":"130","author":"Baranyi","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2026.104622_b0275","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1038\/s41467-024-47771-x","article-title":"Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma","volume":"15","author":"Pucci","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104622_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105546","article-title":"Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)","volume":"122","author":"Shu","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.drudis.2026.104622_b0285","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41565-021-01000-4","article-title":"Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells","volume":"17","author":"Saha","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.drudis.2026.104622_b0290","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/cbic.201900573","article-title":"Role of post-translational modifications in Alzheimer's disease","volume":"21","author":"Ramesh","year":"2020","journal-title":"Chembiochem"},{"key":"10.1016\/j.drudis.2026.104622_b0295","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40478-021-01231-5","article-title":"Protein farnesylation is upregulated in Alzheimer's human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer's model mice","volume":"9","author":"Jeong","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.drudis.2026.104622_b0300","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13024-022-00561-9","article-title":"Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice","volume":"17","author":"Cuddy","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.drudis.2026.104622_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.628283","article-title":"Bacteria are new targets for inhibitors of human farnesyltransferase","volume":"12","author":"Weber","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.drudis.2026.104622_b0310","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41467-024-45241-y","article-title":"Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor","volume":"15","author":"Sake","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104622_b0315","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-024-01858-5","article-title":"Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104622_b0320","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jgar.2022.11.011","article-title":"Effect of farnesyltransferase inhibitors on SARS-CoV-2","volume":"32","author":"Weber","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.drudis.2026.104622_b0325","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41557-019-0237-6","article-title":"Dual chemical probes enable quantitative system-wide analysis of protein prenylation and prenylation dynamics","volume":"11","author":"Storck","year":"2019","journal-title":"Nat Chem"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:01:37Z","timestamp":1777611697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1359644626000279"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104622","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting farnesyltransferase for cancer therapy and beyond","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104622"}}